Mr Robert Klupacs
Mr. Robert Klupacs became CEO of Bionics Institute on 1 May 2017.
He is a highly experienced professional uniquely experienced in translating and commercialising early stage intellectual property from a variety of technology areas into commercial product or investable corporate vehicles.
Mr. Robert Klupacs is an Australian registered patent attorney who has had a wide and successful career to date within both private and publicly traded companies as well as the academic arena.
He has over 30 year’s corporate experience in the international technology development. He has focused primarily on medtech and biotechnology and biotechnology corporate development, particularly healthcare related, but has also been involved in the commercialisation of software, scientific instrumentation, food technologies and enabling agricultural technology.
Mr. Robert Klupacs was previously Director, Intellectual Property AMRAD, Chief Operating Officer of Monash Institute of Reproduction and Development, CEO of the Singapore based ES Cell International, Managing Director and CEO of ASX listed Circadian Technologies Ltd, and Executive Chairman of Bionic Vision Pty Ltd. Prior to joining Bionics Institute he ran his own boutique technology development advisory company Magdajano Pty Ltd. He has been a Non-executive Director for a number of early stage companies and CRC’s and currently is a Non-executive Director of Bionic Vision Technologies Pty Ltd and ASX listed Bio-Gene Technology Limited.
He has a deep expertise and experience in all facets of corporate development and technology transfer including: IP licensing, patenting, intellectual property strategy and management, joint venture creation and management, fund-raising (private and public markets), corporate and scientific due diligence, technology and corporate acquisitions, corporate compliance and corporate governance and academic liaison. He is the Founder of 24 companies in Australia and Singapore.
He is especially regarded for his ability to bridge cultural divides and knowledge gaps between academics, corporations and the general investment community.
He is internationally recognised for his ability to lead start-up organisations to mature well focused companies; strong leadership; organizational and communication skills and his track record of consistent and exceptional achievement.
He was previously a member of the Pharmaceutical Industry Group and the Victorian Biotechnology Advisory Committee.
He is scientifically trained in pharmacology and biochemistry and has a deep understanding of molecular biology, genetics, bioinformatics, neurosciences, immunology, ophthalmology (device and therapeutic), oncology, reproductive biology and stem cell biology.
He is also heavily involved in raising funds for autism research through his role as pro-bono Non-executive Chairman of the registered charity Bioautism Limited.